

This document is an English-translated version of an attachment of a notification for Revision of PRECAUTIONS issued by the Ministry of Health, Labour and Welfare.

This English version is intended to be a reference material to provide convenience for users.

In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of PRECAUTIONS

Ceritinib

May 20, 2025

Therapeutic category

Other antitumor agents

Non-proprietary name

Ceritinib

Safety measure

PRECAUTIONS should be revised.

Revised language is underlined.

Current	Revision		
2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.) (N/A)	2. CONTRAINDICATIONS (This drug is contraindicated to the following patients.) <u>Patients receiving the following drug: Venetoclax (relapsed or refractory chronic lymphocytic leukaemia (including small lymphocytic lymphoma) and relapsed or refractory mantle cell lymphoma during the dose escalation phase)</u>		
10. INTERACTIONS (N/A)	10. INTERACTIONS 10.1 Contraindications for Co-administration (Do not co-administer with the following.)		
	Drugs	Signs, symptoms, and treatment	Mechanism/risk factors
	<u>Venetoclax</u> (relapsed or refractory chronic lymphocytic leukaemia (including small lymphocytic lymphoma) and relapsed or refractory mantle cell lymphoma during the dose escalation phase)	<u>The occurrence of tumour lysis syndrome may increase.</u>	Strong CYP3A inhibition by ceritinib may suppress the metabolism of venetoclax, leading to an increase in the blood concentration of venetoclax.